Search

Objective The aim of the study is to compare perinatal outcomes for women with greater social needs, as identified by the Community Health Needs Assessment, to those of women living in other areas of the county. Study Design This was a retrospective cohort study of pregnant women delivering at a large inner-city county hospital. Perinatal outcomes were analyzed for women living within a target area with substantial health disparities and social needs, and compared with those women living outside the target area. Statistical analysis included student's t -test, Chi square, and logistic regression. Results Between January 2015 and July 2020, 66,936 women delivered at Parkland hospital. Of these, 7,585 (11%) resided within the target area. These women were younger (26.8 ± 6.5 vs. 27.9 ± 6.4 years, p < 0.001), more likely to be black (37 vs. 13%, p < 0.001), and had a higher body mass index or BMI (33.3 ± 7.0 vs. 32.6 ± 6.4 kg/m 2 , p < 0.001). All women were likely to access prenatal care, with 7,320 (96.5%) in the target area and 57,677 (97.2%) outside the area attending at least one visit. Adverse perinatal outcomes were increased for women living within the target area, which persisted after adjustment for age, race, and BMI. This included an increased risk of preeclampsia (adjusted risk ratio [aRR] 1.1, 95% confidence interval or CI [1.03, 1.2]) and abruption (aRR 1.3, 95% CI [1.1, 1.7]), as well as preterm birth before both 34 weeks (aRR 1.3, 95% CI [1.2, 1.5]) and 28 weeks (aRR 1.3, 95% CI [1.02,1.7]). It follows that neonatal ICU admission (aRR 2.1, 95% CI [1.3, 3.4]) and neonatal death (aRR 1.2, 95% CI [1.1, 1.3]) were increased within the target area. Interestingly, rate of postpartum visit attendance was higher in the target area (57 vs. 48%), p < 0.001. Conclusion Even among vulnerable populations, women in areas with worse health disparities and social needs are at greater risk of adverse perinatal outcomes. Efforts to achieve health equity will need to address social disparities. Key Points At a county hospital, 97% of women accessed prenatal care. Greater social needs were associated with adverse perinatal outcomes. Differences persisted with adjustment for age, race, and BMI. [ABSTRACT FROM AUTHOR]

The US Preventive Services Task Force (USPSTF) recently released a Recommendation Statement on screening for iron deficiency anemia in pregnancy and found insufficient evidence to support routine screening or preventive iron supplementation. The USPSTF emphasized the need for more studies and clinical trials in the obstetric population, as pregnant patients have historically been excluded from research. The review included randomized clinical trials (RCTs) and highlighted the limitations of RCTs in studying rare outcomes and their lack of real-world applicability. The USPSTF also discussed the importance of assessing physiologically plausible outcomes and the need for an evidence-based definition of iron deficiency anemia in pregnancy. The benefits of screening for iron deficiency without anemia were also inconclusive. Despite the knowledge gaps, the USPSTF acknowledged the minimal risk of harm and improved hematologic indices associated with routine iron supplementation in pregnancy. The article concludes by emphasizing the importance of considering health-related social needs and widening the lens to understand the factors that contribute to iron deficiency anemia in pregnancy. [Extracted from the article]

Objective The aim of the study is to evaluate whether pathologic severity of placenta accreta spectrum (PAS) is correlated with the incidence of small for gestational age (SGA) and neonatal birthweight. Study Design This was a multicenter cohort study of viable, non-anomalous, singleton gestations delivered with histology-proven PAS. Data including maternal history, neonatal birthweight, and placental pathology were collected and deidentified. Pathology was defined as accreta, increta, or percreta. The primary outcome was rate of SGA defined by birth weight less than the 10th percentile. The secondary outcomes included incidence of large for gestational age (LGA) babies as defined by birth weight greater than the 90th percentile as well as incidence of SGA and LGA in preterm and term gestations. Statistical analysis was performed using Chi-square, Kruskal–Wallis, and log-binomial regression. Increta and percreta patients were each compared with accreta patients. Results Among the cohort of 1,008 women from seven United States centers, 865 subjects were included in the analysis. The relative risk (RR) of SGA for increta and percreta did not differ from accreta after adjusting for confounders (adjusted RR = 0.63, 95% confidence interval [CI]: 0.36–1.10 for increta and aRR = 0.72, 95% CI: 0.45–1.16 for percreta). The results were stratified by placenta previa status, which did not affect results. There was no difference in incidence of LGA (p = 1.0) by PAS pathologic severity. The incidence of SGA for all PAS patients was 9.2% for those delivered preterm and 18.7% for those delivered at term (p = 0.004). The incidence of LGA for all PAS patients was 12.6% for those delivered preterm and 13.2% for those delivered at term (p = 0.8203). Conclusion There was no difference in incidence of SGA or LGA when comparing accreta to increta or percreta patients regardless of previa status. Although we cannot suggest causation, our results suggest that PAS, regardless of pathologic severity, is not associated with pathologic fetal growth in the preterm period. Key Points PAS severity is not associated with SGA in the preterm period. PAS severity is not associated with LGA. Placenta previa does not affect the incidence of SGA in women with PAS. [ABSTRACT FROM AUTHOR]

Due to a nationwide shortage of Ringer's lactate, normal saline became the intravenous fluid of choice at our institution in May 2018. Recent studies have shown that the administration of normal saline in critically ill patients may have adverse renal effects. Our objective was to evaluate the renal function effects; if any, of normal saline administered to women with preeclampsia receiving magnesium sulfate. This is a prospective observational study of women identified with preeclampsia with severe features, requiring magnesium sulfate prophylaxis. The amount of normal saline administered was calculated and a basic metabolic panel was surveyed 12 h after initiation of magnesium sulfate prophylaxis. Laboratory analytes were examined according to the volume of intravenous normal saline received, including a comparison to those women who did not receive normal saline, to determine the impact of parameters after 12 h of magnesium sulfate prophylaxis. From May 2018 to November 2018, a total of 233 patients receiving magnesium sulfate were identified, 184 of which had received intravenous normal saline. No differences were identified at 12 h in serum chloride or creatinine between those patients who received intravenous normal saline and those who did not. This finding persisted when serum chloride and creatinine were analyzed across quartiles of normal saline received. Interestingly, serum calcium was found to decrease with increasing serum magnesium (p <.001). This association was also dependent upon the amount of intravenous fluids received (p <.001) when controlling for serum magnesium. Renal function indices were preserved despite the introduction of normal saline with oxytocin into routine practice. No dose–response relationship was identified when serum chloride and creatinine were analyzed across quartiles of normal saline received. Interestingly, serum calcium levels were noted to decline with both the amount of intravenous fluid received as well as with increasing serum magnesium levels. [ABSTRACT FROM AUTHOR]